Figure 3.
Improved disease control by Blimp-1 KO CAR T cells in a myeloma mouse model. (A-E) UT cells or Mock or Blimp-1 KO CAR T cells were injected into mice previously infused with luciferase-expressing ARP-1 (ARP-1-ffLuc) cells. (A) Schematic showing experimental plan. (B-C) Disease progression, observed as bioluminescence signal from weekly images of mice. Displayed are photos (B) and quantification (C) from individual mice. (D) Quantification of bioluminescence on day 28, showing means ± SD (1-way analysis of variance [ANOVA] with Tukey multiple comparisons test). (E) Overall survival of animals from each group. Arrows in the panels C,E show days on which T cells/CAR T cells were infused. Dotted line in the panel C indicates bioluminescence threshold for euthanizing mice (3 × 108 p/s/cm2/sr).

Improved disease control by Blimp-1 KO CAR T cells in a myeloma mouse model. (A-E) UT cells or Mock or Blimp-1 KO CAR T cells were injected into mice previously infused with luciferase-expressing ARP-1 (ARP-1-ffLuc) cells. (A) Schematic showing experimental plan. (B-C) Disease progression, observed as bioluminescence signal from weekly images of mice. Displayed are photos (B) and quantification (C) from individual mice. (D) Quantification of bioluminescence on day 28, showing means ± SD (1-way analysis of variance [ANOVA] with Tukey multiple comparisons test). (E) Overall survival of animals from each group. Arrows in the panels C,E show days on which T cells/CAR T cells were infused. Dotted line in the panel C indicates bioluminescence threshold for euthanizing mice (3 × 108 p/s/cm2/sr).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal